The Filing Desk

Dare Bioscience vs NRX Pharmaceuticals

Dare Bioscience DARE · NRX Pharmaceuticals NRXP · Pharmaceuticals

NRX Pharmaceuticals reported revenue of $1 million in fiscal 2025, 1.2 times Dare Bioscience's $1 million in fiscal 2025. Dare Bioscience had an operating margin of -1315.5%, against -1324.4% at NRX Pharmaceuticals.

Side by side

Dare BioscienceNRX Pharmaceuticals
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$1M$1M
Revenue growth10,429.4%—
Revenue growth a year, last 5 years——
Gross margin71.3%58.8%
Operating margin−1,315.5%−1,324.4%
Net margin−1,300.7%−2,336.5%
Free cash flow−$10M—
Free cash flow margin−997.0%—
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count31.6%101.1%
Last close$0.45$2.55
P/E at the last close——
Insider trades, last 12 months——
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Dare BioscienceNRX Pharmaceuticals
Operating margin
Percent of revenue
Dare BioscienceNRX Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Dare BioscienceNRX Pharmaceuticals

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Dare Bioscience and NRX Pharmaceuticals pages.